National Institutes of Health, a Component of the US Dept. of Health & Human Services

Medimmune Limited

The United States of America

US Government As Represented by the Secretary of the Army

The United States of America As Represented by the Department of Health

The Scripps Research Institute

St. Jude Children's Research Hospital

Intracel Resources LLC

The Walter Reed Army Institute of Research

Other

American Home Products Corporation

National Institute of Health

Brian R Murphy

Stephen Whitehead

Peter L Collins

Joseph E Blaney

Ching-Juh Lai

Robert M Chanock

Kathryn A Hanley

Mario H Skiadopoulos

Ursula J Buchholz

James E Crowe, Jr

Alexander G Pletnev

Lewis Markoff

Barry Falgout

Christine D Krempl

Anna P Durbin

Joseph R Putnak

Richard S Bennett

George William Kemble

Chin-Fen Yang

Alexander C Schmidt

Tao Tao

Joseph E Blaney, Jr

Dennis R Burton

Carlos F Barbas, Iii

Kanta Subbarao

Cindy Luongo

Alexander A Bukreyev

Mark Connors

Robert G Webster

Alan R Davis

Michael D Lubeck

Kuo-Hom L Hsu

Katalin Juhasz

Michael N Teng

Amber R Engel

Jane E Bailly

Alison Bermingham

Bernard H Selling

Glenn R Pilkington

Virginia S Hinshaw

Page S Gilmour

Albert Z Kapikian

Yasutaka Hoshino

Timo Vesikari

Mary Elaine La Montagne, Legal Representative

Stephane Biacchesi

Jason T Newman

Sheila Nolan

Kanta Subbaro

Lone Simonsen

David M Morens

John R La Montagne

Cindy L Luongo

Ann-Marie M Cruz

Stephen S Whitehead

Peter L Colins

Emmalene J Barlett

The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3' untranslated region (3′-UTR) comprising a Δ30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR that removes sequence in the 5′ direction as far as the 5′ boundary of the TL-3 homologous structure in each of the dengue serotypes 1, 2, 3, and 4, or a replacement of the 3′-UTR of a dengue virus of a first serotype with the 3′-UTR of a dengue virus of a second serotype, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.

Development of dengue virus vaccine components

The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (&#x394;30) in the 3'-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.

Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4

The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3' untranslated region (3&#x2032;-UTR) comprising a &#x394;30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the &#x394;30 mutation deleted from the 3&#x2032;-UTR that removes sequence in the 5&#x2032; direction as far as the 5&#x2032; boundary of the TL-3 homologous structure in each of the dengue serotypes 1, 2, 3, and 4, or a replacement of the 3&#x2032;-UTR of a dengue virus of a first serotype with the 3&#x2032;-UTR of a dengue virus of a second serotype, optionally containing the &#x394;30 mutation and nucleotides additional to the &#x394;30 mutation deleted from the 3&#x2032;-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.

The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines,

Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus

A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.

Attenuated mutant dengue viruses comprising a mutation in the NS5 non-structural protein

Provided herein are recombinant respiratory syncytial viruses that contain mutations that make the disclosed viruses attractive vaccine candidates. The viruses disclosed contain attenuating mutations designed to have increased genetic and phenotypic stability. Desired combinations of these mutations can be made to achieve desired levels of attenuation. Exemplary vaccine candidates are described. Also provided are polynucleotides capable of encoding the described viruses, as wells as methods for producing the viruses and methods of use.

Genetically stable live attenuated respiratory syncytial virus vaccine and its production

The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.

Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4

The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.

Live attenuated virus vaccines for La Crosse virus and other bunyaviridae

Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses

Provided herein are recombinant respiratory syncytial viruses that contain mutations that make the disclosed viruses attractive vaccine candidates. The viruses disclosed contain attenuating mutations designed to have increased genetic and phenotypic stability. Desired combinations of these mutations can be made to achieve desired levels of attenation. Exemplary vaccine candidates are described. Also provided are polynucleotides capable of encoding the described viruses, as wells as methods for producing the viruses and methods of use.

Live attenuated virus vaccines for la crosse virus and other bunyaviridae

Growing community of inventors

Bethesda, MD, United States of America

Brian R Murphy